Biogen Idec gets global rights to Knopp's ALS candidate; Deal terminated
Knopp Neurosciences Inc. has licensed Biogen Idec Inc. exclusive worldwide rights to develop and commercialize Phase II KNS760704 (dexpramipexole) for amyotrophic lateral sclerosis and other indications.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com